



## **CERTIFICATE OF COMPLETION**

THE UNIVERSITY OF WASHINGTON AND NATIONAL HIV CURRICULUM CERTIFY THAT

## Justin Hooks, MSN

HAS COMPLETED THE FOLLOWING LESSONS IN THE

## CO-OCCURRING CONDITIONS 3RD EDITION MODULE

Latent Tuberculosis Infection, Opportunistic Infections: Prevention, Opportunistic Infections: Treatment, Sexually Transmitted Diseases, Hepatitis B Coinfection, and Hepatitis C Coinfection

David H. Spach, MD

Editor-in-Chief, National HIV Curriculum Professor of Medicine, University of Washington



This certificate shows the progress of **Justin Hooks, MSN**, a Nurse Practitioner, identified by **justin.hooks02@gmail.com** as of August 20, 2025, 3:57 am. You may validate this certificate or obtain a digital copy by visiting https://www.hiv.uw.edu/certificate/co-occurring-conditions/justin.hooks02@gmail.com/3

## The following Lessons were completed along with their quizzes with a quiz score of 80% or higher:

Lessons	Learning Objectives
Latent Tuberculosis Infection Completed April 20, 2024	<ul> <li>Discuss the epidemiology of tuberculosis and HIV coinfection in the United States</li> <li>State the rationale for screening for latent TB in people with HIV</li> <li>Describe and compare recommended screening tests for latent TB in people with HIV</li> <li>List recommended options for the treatment of latent TB in people with HIV</li> <li>Summarize common drug interactions between medications used to treat latent TB and common antiretroviral medications</li> </ul>
Opportunistic Infections: Prevention Completed April 20, 2024	<ul> <li>Discuss recommendations for initiating primary prevention of opportunistic infections in people with HIV</li> <li>Summarize recommendations for initiating secondary prophylaxis of opportunistic infections in people with HIV</li> <li>State criteria for discontinuing primary prevention of opportunistic infections in people with HIV</li> <li>List criteria for discontinuing secondary prophylaxis of opportunistic infections in people with HIV</li> <li>Recognize potential adverse effects and contraindications for medications used for prevention of opportunistic infections</li> </ul>
Opportunistic Infections: Treatment Completed April 20, 2024	<ul> <li>Describe trends in the incidence of opportunistic infections in people with HIV</li> <li>Recognize the clinical manifestations of common serious opportunistic infections that occur in people with HIV</li> <li>Discuss recommended treatment of common opportunistic infections</li> <li>List indications for discontinuing treatment for opportunistic infections</li> <li>Summarize recommendations for initiating antiretroviral therapy in the setting of an active opportunistic infection</li> </ul>
Sexually Transmitted Infections (Sexually Transmitted Diseases) Completed April 20, 2024	<ul> <li>Describe the recommendations for sexually transmitted infection screening in people with HIV</li> <li>Summarize CDC recommendations for the treatment of common sexually transmitted infections in people with HIV</li> <li>Explain the different stages of syphilis and the recommended treatments at each stage</li> <li>Discuss laboratory-based methods for diagnosing syphilis</li> <li>List recommended treatment and suppressive treatment options for genital herpes in people with HIV</li> </ul>
Hepatitis B Coinfection Completed April 20, 2024	<ul> <li>Identify appropriate tests for evaluation of hepatitis B virus (HBV) infection and immunity</li> <li>Summarize the approach to persons with HIV who have isolated hepatitis B core antibody</li> <li>Discuss antiretroviral management of persons with HIV and HBV coinfection</li> <li>Describe HBV-related immune reconstitution syndrome</li> <li>List indications and methods for hepatocellular carcinoma surveillance in persons with chronic HBV and HIV coinfection</li> </ul>
Hepatitis C Coinfection Completed April 20, 2024	<ul> <li>Explain recommendations for HCV screening in people with HIV</li> <li>Describe the appropriate HCV testing algorithm</li> <li>Summarize the eligibility criteria and current guidelines for the simplified HCV treatment in people with HIV</li> <li>Discuss simplified HCV treatment regimens options for people with HIV</li> <li>List indications and methods for hepatocellular carcinoma surveillance in persons with chronic HCV and HIV</li> </ul>